Nektar Therapeutics (NASDAQ:NKTR) price on Thursday, January 16, fall -1.50% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.89.
A look at the stock’s price movement, the close in the last trading session was $0.91, moving within a range at $0.8802 and $0.9159. The beta value (5-Year monthly) was 0.61. Turning to its 52-week performance, $1.93 and $0.48 were the 52-week high and 52-week low respectively. Overall, NKTR moved -11.71% over the past month.
Nektar Therapeutics’s market cap currently stands at around $164.48 million, with investors looking forward to this quarter’s earnings report slated for in February.
Analysts have a consensus estimate of 36.65M for the company’s revenue for the quarter, with a low and high estimate of 17.58M and 91M respectively. The average forecast suggests up to a 53.46% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 105.92M, representing a 17.53% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NKTR is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend NKTR as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NKTR’s current price about -9.23% and -16.91% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 38.48, while 7-day volatility ratio is 8.91% and 8.44% in the 30-day chart. Further, Nektar Therapeutics (NKTR) has a beta value of 0.59, and an average true range (ATR) of 0.09. Analysts have given the company’s stock an average 52-week price target of $18.5, forecast between a low of $6 and high of $24. Looking at the price targets, the low is -574.16% off current price level while to achieve the yearly target high, price needs to move -2596.63%. Nonetheless, investors will most likely welcome a -1978.65% jump to $18.5 which is the analysts’ median price.
If we refocus on Nektar Therapeutics (NASDAQ:NKTR), historical trading data shows that trading volumes averaged 1.77 over the past 10 days and 1.88 million over the past 3 months. The company’s latest data on shares outstanding shows there are 184.46 million shares.
The 3.64% of Nektar Therapeutics’s shares are in the hands of company insiders while institutional holders own 74.36% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.35 million on 2024-12-31, giving us a short ratio of 2.26. The data shows that as of 2024-12-31 short interest in Nektar Therapeutics (NKTR) stood at 301.0 of shares outstanding, with shares short falling to 4.44 million registered in 2024-11-29. Current price change has pushed the stock -4.12% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NKTR stock continues to rise going into the next quarter.
